In spite of use of cannabidiol (CBD), a non-psychoactive cannabinoid, in pediatric patients with epilepsy, preclinical studies on its effects in immature animals are very limited. In the present study we investigated anti-seizure activity of CBD (10 and 60 mg/kg administered intraperitoneally) in two models of chemically induced seizures in infantile (12-days old) rats. Seizures were induced either with pentylenetetrazol (PTZ) or N-methyl-D-aspartate (NMDA). In parallel, brain and plasma levels of CBD and possible motor adverse effects were assessed in the righting reflex and the bar holding tests. CBD was ineffective against NMDA-induced seizures, but in a dose 60 mg/kg abolished the tonic phase of PTZ-induced generalized seizures. Plasma and brain levels of CBD were determined up to 24 h after administration. Peak CBD levels in the brain (996 ± 128 and 5689 ± 150 ng/g after the 10- and 60-mg/kg doses, respectively) were reached 1-2 h after administration and were still detectable 24 h later (120 ± 12 and 904 ± 63 ng/g, respectively). None of the doses negatively affected motor performance within 1 h after administration, but CBD in both doses blocked improvement in the bar holding test with repeated exposure to this task. Taken together, anti-seizure activity of CBD in infantile animals is dose and model dependent, and at therapeutic doses CBD does not cause motor impairment. The potential risk of CBD for motor learning seen in repeated motor tests has to be further examined.

Department of Experimental Neurobiology National Institute of Mental Health Klecany Topolová 748 250 67 Klecany Czech Republic

Department of Psychiatry and Medical Psychology 3FM CU and NIMH 3rd Faculty of Medicine Charles University Prague Ruská 87 100 00 Prague Czech Republic

Institute of Forensic Medicine and Toxicology 1st Faculty of Medicine Charles University and General University Hospital Prague 121 08 Prague Czech Republic

Laboratory of Developmental Epileptology Institute of Physiology Czech Academy of Sciences Vídeňská 1083 142 20 Prague Czech Republic

Zobrazit více v PubMed

Alexander S.P.H. Therapeutic potential of cannabis-related drugs. Prog. Neuro Psychopharmacol. Biol. Psychiatry. 2016;64:157–166. doi: 10.1016/j.pnpbp.2015.07.001. PubMed DOI

Bhattacharyya S., Morrison P.D., Fusar-Poli P., Martin-Santos R., Borgwardt S., Wintonbrown T.T., Nosarti C., Carroll C.M.O., Seal M.L., Allen P., et al. Opposite effects of δ-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35:764–774. doi: 10.1038/npp.2009.184. PubMed DOI PMC

Englund A., Morrison P.D., Nottage J.F., Hague D., Kane F., Bonaccorso S., Stone J.M., Reichenberg A., Brenneisen R., Holt D., et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J. Psychopharmacol. 2013;27:19–27. doi: 10.1177/0269881112460109. PubMed DOI

Hayakawa K., Mishima K., Fujiwara M. Therapeutic Potential of Non-Psychotropic Cannabidiol in Ischemic Stroke. Pharmaceuticals. 2010;3:2197–2212. doi: 10.3390/ph3072197. PubMed DOI PMC

McGuire P., Robson P., Cubała W., Vasile D., Morrison P.D., Barron R., Taylor A., Wright S. Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial. Am. J. Psychiatry. 2018;175:225–231. doi: 10.1176/appi.ajp.2017.17030325. PubMed DOI

Resstel L.B.M., Joca S.R.L., Moreira F.A., Correa F.M.A., Guimaraes F.S. Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Behav. Brain Res. 2006;172:294–298. doi: 10.1016/j.bbr.2006.05.016. PubMed DOI

Schiavon A.P., Bonato J.M., Milani H., Guimaraes F.S., de Oliveira R.M.W. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Prog. Neuro Psychopharmacol. Biol. Psychiatry. 2016;64:27–34. doi: 10.1016/j.pnpbp.2015.06.017. PubMed DOI

Devinsky O., Cross H., Laux L., Marsh E., Miller I., Nabbout R., Scheffer I., Thiele E.A., Wright S. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N. Engl. J. Med. 2017;376:2011–2020. doi: 10.1056/NEJMoa1611618. PubMed DOI

Devinsky O., Patel A.D., Cross H., Villanueva V., Wirrell E.C., Privitera M., Greenwood S.M., Roberts C., Checketts D., VanLandingham K.E., et al. Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome. N. Engl. J. Med. 2018;378:1888–1897. doi: 10.1056/NEJMoa1714631. PubMed DOI

Corroon J., Kight R. Regulatory Status of Cannabidiol in the United States: A Perspective. Cannabis Cannabinoid Res. 2018;3:190–194. doi: 10.1089/can.2018.0030. PubMed DOI PMC

Izquierdo I., Tannhauser M. Letter: The effect of cannabidiol on maximal electroshock seizures in rats. J. Pharm. Pharmacol. 1973;25:916–917. doi: 10.1111/j.2042-7158.1973.tb09976.x. PubMed DOI

Chesher G.B., Dahl C.J., Everingham M., Jackson D.M., Marchant-Williams H., Starmer G.A. The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br. J. Pharmacol. 1973;49:588–594. doi: 10.1111/j.1476-5381.1973.tb08534.x. PubMed DOI PMC

Franco V., Perucca E. Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy. Drugs. 2019;79:1435–1454. doi: 10.1007/s40265-019-01171-4. PubMed DOI

Franco V., Bialer M., Perucca E. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. Neuropharmacology. 2021;185:108442. doi: 10.1016/j.neuropharm.2020.108442. PubMed DOI

Rosenberg E.C., Tsien R.W., Whalley B.J., Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics. 2015;12:747–768. doi: 10.1007/s13311-015-0375-5. PubMed DOI PMC

Senn L., Cannazza G., Biagini G. Receptors and channels possibly mediating the effects of phytocannabinoids on seizures and epilepsy. Pharmaceuticals. 2020;13:174. doi: 10.3390/ph13080174. PubMed DOI PMC

Benn E.K., Hauser W.A., Shih T., Leary L., Bagiella E., Dayan P., Green R., Andrews H., Thurman D.J., Hesdorffer D.C. Estimating the incidence of first unprovoked seizure and newly diagnosed epilepsy in the low-income urban community of Northern Manhattan, New York City. Epilepsia. 2008;49:1431–1439. doi: 10.1111/j.1528-1167.2008.01564.x. PubMed DOI

Cowan L.D. The epidemiology of the epilepsies in children. Ment. Retard. Dev. Disabil. Res. Rev. 2002;8:171–181. doi: 10.1002/mrdd.10035. PubMed DOI

Clancy B., Darlington R.B., Finlay B.L. Translating developmental time across mammalian species. Neuroscience. 2001;105:7–17. doi: 10.1016/S0306-4522(01)00171-3. PubMed DOI

Workman A.D., Charvet C.J., Clancy B., Darlington R.B., Finlay B.L. Modeling transformations of neurodevelopmental sequences across mammalian species. J. Neurosci. 2013;33:7368–7383. doi: 10.1523/JNEUROSCI.5746-12.2013. PubMed DOI PMC

Ellingson R.J. Studies of the Electrical Activity of the Developing Human Brain. Prog. Brain Res. 1964;9:26–53. doi: 10.1016/S0079-6123(08)63130-1. DOI

Mares P., Velisek L. N-methyl-D-aspartate (NMDA)-induced seizures in developing rats. Dev. Brain Res. 1992;65:185–189. doi: 10.1016/0165-3806(92)90178-Y. PubMed DOI

Klein B.D., Jacobson C.A., Metcalf C.S., Smith M.D., Wilcox K.S., Hampson A.J., Kehne J.H. Evaluation of Cannabidiol in Animal Seizure Models by the Epilepsy Therapy Screening Program (ETSP) Neurochem. Res. 2017;42:1939–1948. doi: 10.1007/s11064-017-2287-8. PubMed DOI

Huizenga M.N., Sepulveda-Rodriguez A., Forcelli P.A. Preclinical safety and efficacy of cannabidivarin for early life seizures. Neuropharmacology. 2019;148:189–198. doi: 10.1016/j.neuropharm.2019.01.002. PubMed DOI PMC

Staňková L., Kubová H., Mareš P. Anticonvulsant action of lamotrigine during ontogenesis in rats. Epilepsy Res. 1992;13:17–22. doi: 10.1016/0920-1211(92)90003-C. PubMed DOI

Kubová H., Maresš P. Anticonvulsant Action of Oxcarbazepine, Hydroxycarbamazepine, and Carbamazepine Against Metrazol-Induced Motor Seizures in Developing Rats. Epilepsia. 1993;34:188–192. doi: 10.1111/j.1528-1157.1993.tb02397.x. PubMed DOI

Haugvicová R., Kubová H., Mareš P. Qualitative changes of anticonvulsant action of felbamate during development in rats. Brain Dev. 1998;20:222–226. doi: 10.1016/S0387-7604(98)00030-8. PubMed DOI

Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 2011;20:359–368. doi: 10.1016/j.seizure.2011.01.003. PubMed DOI

Kabova R., Liptakova S., Slamberova R., Pometlova M., Velisek L. Age-specific N-methyl-D-aspartate-induced seizures: Perspectives for the West syndrome model. Epilepsia. 1999;40:1357–1369. doi: 10.1111/j.1528-1157.1999.tb02006.x. PubMed DOI

Herlopian A., Hess E.J., Barnett J., Geffrey A.L., Pollack S.F., Skirvin L., Bruno P., Sourbron J., Thiele E.A. Cannabidiol in treatment of refractory epileptic spasms: An open-label study. Epilepsy Behav. 2020;106:106988. doi: 10.1016/j.yebeh.2020.106988. PubMed DOI

Rodríguez-Muñoz M., Onetti Y., Cortés-Montero E., Garzón J., Sánchez-Blázquez P. Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor 11 Medical and Health Sciences 1109 Neurosciences 11 Medical and Health Sciences 1115 Pharmacology and Pharmaceutical Scien. Mol. Brain. 2018;11:1–12. doi: 10.1186/s13041-018-0395-2. PubMed DOI PMC

Macdonald R.L., Barker J.L. Specific antagonism of GABA-mediated postsynaptic inhibition in cultured mammalian spinal cord neurons: A common mode of convulsant action. Neurology. 1978;28:325–330. doi: 10.1212/WNL.28.4.325. PubMed DOI

Kubová H., Folbergrová J., Mares P. Seizures induced by homocysteine in rats during ontogenesis. Epilepsia. 1995;36:750–756. doi: 10.1111/j.1528-1157.1995.tb01611.x. PubMed DOI

Mares P., Folbergrová J., Langmeier M., Haugvicová R., Kubová H. Convulsant action of D,L-homocysteic acid and its stereoisomers in immature rats. Epilepsia. 1997;38:767–776. doi: 10.1111/j.1528-1157.1997.tb01463.x. PubMed DOI

Insel T.R., Miller L.P., Gelhard R.E. The ontogeny of excitatory amino acid receptors in rat forebrain—I. N-methyl-D-aspartate and quisqualate receptors. Neuroscience. 1990;35:31–43. doi: 10.1016/0306-4522(90)90117-m. PubMed DOI

Tsumoto T., Hagihara K., Sato H., Hata Y. NMDA receptors in the visual cortex of young kittens are more effective than those of adult cats. Nature. 1987;327:513–514. doi: 10.1038/327513a0. PubMed DOI

Hamon B., Heinemann U. Developmental changes in neuronal sensitivity to excitatory amino acids in area CA1 of the rat hippocampus. Brain Res. 1988;466:286–290. doi: 10.1016/0165-3806(88)90054-5. PubMed DOI

Kubová H. Ontogenesis and treatment efficacy: Prevention of seizures in the immature brain. Adv. Neurol. 1999;81:357–361. PubMed

Kubová H., Mares P. Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats. Epilepsia. 2010;51:469–472. doi: 10.1111/j.1528-1167.2009.02305.x. PubMed DOI

Bittigau P., Sifringer M., Genz K., Reith E., Pospischil D., Govindarajalu S., Dzietko M., Pesditschek S., Mai I., Dikranian K., et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc. Natl. Acad. Sci. USA. 2002;99:15089–15094. doi: 10.1073/pnas.222550499. PubMed DOI PMC

Ikonomidou C., Turski L. Antiepileptic drugs and brain development. Epilepsy Res. 2010;88:11–22. doi: 10.1016/j.eplepsyres.2009.09.019. PubMed DOI

Altman J., Sudarshan K. Postnatal development of locomotion in the laboratory rat. Anim. Behav. 1975;23:896–920. doi: 10.1016/0003-3472(75)90114-1. PubMed DOI

Jänicke B., Schulze G., Coper H. Motor performance achievements in rats of different ages. Exp. Gerontol. 1983;18:393–407. doi: 10.1016/0531-5565(83)90018-9. PubMed DOI

Deiana S., Watanabe A., Yamasaki Y., Amada N., Arthur M., Fleming S., Woodcock H., Dorward P., Pigliacampo B., Close S., et al. Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ 9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behav. Psychopharmacology. 2012;219:859–873. doi: 10.1007/s00213-011-2415-0. PubMed DOI

McPhail B.T., White C.A., Cummings B.S., Muralidhara S., Wilson J.T., Bruckner J.V. The immature rat as a potential model for chemical risks to children: Ontogeny of selected hepatic P450s. Chem. Biol. Interact. 2016;256:167–177. doi: 10.1016/j.cbi.2016.07.005. PubMed DOI

Hložek T., Uttl L., Kadeřábek L., Balíková M., Lhotková E., Horsley R.R., Nováková P., Šíchová K., Štefková K., Tylš F., et al. Pharmacokinetic and behavioural profile of THC, CBD, and THC + CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC. Eur. Neuropsychopharmacol. 2017;27:1223–1237. doi: 10.1016/j.euroneuro.2017.10.037. PubMed DOI

Vacek J., Papouskova B., Polanska H., Hönigova K., Storch J., Babula P., Masarik M. CBD is not converted to THC in rats: A framework interpretation and discussion. Eur. Neuropsychopharmacol. 2021;50:135–136. doi: 10.1016/j.euroneuro.2021.04.003. PubMed DOI

Velisek L., Kubova H., Pohl M., Stankova L., Mareš P., Schickerova R. Pentylenetetrazol-induced seizures in rats: An ontogenetic study. Naunyn Schmiedeberg’s Arch. Pharmacol. 1992;346:588–591. doi: 10.1007/BF00169017. PubMed DOI

Pohl M., Mares P. Effects of flunarizine on Metrazol-induced seizures in developing rats. Epilepsy Res. 1987;1:302–305. doi: 10.1016/0920-1211(87)90006-4. PubMed DOI